Ari Zimran

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 43

Top Topics

Replacement Therapy

Duchenne Muscular Dystrophy

Stem Cell Transplantation

Top Venues

Journal of clinical medicine

International journal of molecular sciences

American journal of hematology

Movement disorders : official journal of the Movement Disorder Society

This page only lists publications with an associated author ORCID identifier.

Publications

Soojin Hwang, Hyunwoo Bae, Ji-Hee Yoon, Dohyung Kim, Hyo-Sang Do, Sun Hee Heo, Soyoung Kim, Han Wook Yoo, Majdolen Istaiti, Ari Zimran, Beom-Hee Lee
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease. American journal of hematology 99 (7) (2024)
Aliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti, Volha Skrahina, Jan Lukas, Gilad Yahalom, Mikhal E Cohen, Shoshana Revel-Vilk, Ozlem Goker-Alpan, Michal Becker-Cohen, Sharon Hassin-Baer, Per Svenningsson, Arndt Rolfs, Ari Zimran
GBA1 -Associated Parkinson's Disease Is a Distinct Entity. International journal of molecular sciences 25 (13) (2024)
Soojin Hwang, Hyunwoo Bae, Ji-Hee Yoon, Dohyung Kim, Hyo-Sang Do, Sun Hee Heo, Soyoung Kim, Han Wook Yoo, Majdolen Istaiti, Ari Zimran, Beom-Hee Lee
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease. American journal of hematology 99 (7) (2024)
Aliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti, Volha Skrahina, Jan Lukas, Gilad Yahalom, Mikhal E Cohen, Shoshana Revel-Vilk, Ozlem Goker-Alpan, Michal Becker-Cohen, Sharon Hassin-Baer, Per Svenningsson, Arndt Rolfs, Ari Zimran
GBA1 -Associated Parkinson's Disease Is a Distinct Entity. International journal of molecular sciences 25 (13) (2024)
Deborah Elstein, Nadia Belmatoug, Bruno Bembi, Patrick Deegan, Diego Fernandez-Sasso, Pilar Giraldo, Ozlem Goker-Alpan, Derralynn Hughes, Heather Lau, Elena Lukina, Shoshana Revel-Vilk, Ida Vanessa D Schwartz, Majdolen Istaiti, Jaco Botha, Noga Gadir, Jörn Schenk, Ari Zimran, null null
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry. Journal of clinical medicine 13 (12) (2024)
Soojin Hwang, Hyunwoo Bae, Ji-Hee Yoon, Dohyung Kim, Hyo-Sang Do, Sun Hee Heo, Soyoung Kim, Han Wook Yoo, Majdolen Istaiti, Ari Zimran, Beom-Hee Lee
A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease. American journal of hematology (2024)
Aliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti, Volha Skrahina, Jan Lukas, Gilad Yahalom, Mikhal E Cohen, Shoshana Revel-Vilk, Ozlem Goker-Alpan, Michal Becker-Cohen, Sharon Hassin-Baer, Per Svenningsson, Arndt Rolfs, Ari Zimran
GBA1 -Associated Parkinson's Disease Is a Distinct Entity. International journal of molecular sciences 25 (13) (2024)
Deborah Elstein, Nadia Belmatoug, Bruno Bembi, Patrick Deegan, Diego Fernandez-Sasso, Pilar Giraldo, Ozlem Goker-Alpan, Derralynn Hughes, Heather Lau, Elena Lukina, Shoshana Revel-Vilk, Ida Vanessa D Schwartz, Majdolen Istaiti, Jaco Botha, Noga Gadir, Jörn Schenk, Ari Zimran, null null
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry. Journal of clinical medicine 13 (12) (2024)
Noa Hurvitz, Tama Dinur, Shoshana Revel-Vilk, Samuel Agus, Marc Berg, Ari Zimran, Yaron Ilan
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy. Journal of clinical medicine 13 (11) (2024)
Patrick Deegan, Heather Lau, Deborah Elstein, Diego Fernandez-Sasso, Pilar Giraldo, Derralynn Hughes, Ari Zimran, Majdolen Istaiti, Noga Gadir, Jaco Botha, Shoshana Revel-Vilk, null null
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry. Journal of clinical medicine 13 (10) (2024)
Patrick Deegan, Heather Lau, Deborah Elstein, Diego Fernandez-Sasso, Pilar Giraldo, Derralynn Hughes, Ari Zimran, Majdolen Istaiti, Noga Gadir, Jaco Botha, Shoshana Revel-Vilk, null null
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry. Journal of clinical medicine 13 (10) (2024)
Noa Hurvitz, Tama Dinur, Shoshana Revel-Vilk, Samuel Agus, Marc Berg, Ari Zimran, Yaron Ilan
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy. Journal of clinical medicine 13 (11) (2024)
Ari Zimran, Jeffrey Szer, Michal Becker-Cohen, Sjoerd Jens, Claudia Cozma, Shoshana Revel-Vilk
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy. Journal of clinical medicine 12 (6) (2023)
Ido Azuri, Ameer Wattad, Keren Peri-Hanania, Tamar Kashti, Ronnie Rosen, Yaron Caspi, Majdolen Istaiti, Makram Wattad, Yaakov Applbaum, Ari Zimran, Shoshana Revel-Vilk, Yonina C Eldar
A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher Disease. Journal of clinical medicine 12 (16) (2023)
Ari Zimran, Jeffrey Szer, Michal Becker-Cohen, Sjoerd Jens, Claudia Cozma, Shoshana Revel-Vilk
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy. Journal of clinical medicine 12 (6) (2023)
Shoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, Noya Machtiger-Azoulay, David Kuter, Jeffrey Szer, Hanna Rosenbaum, David Cavalcanti Ferreira, Noa Ruhrman-Shahar, Michael P Wajnrajch, Ari Zimran
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study. Journal of clinical medicine 12 (18) (2023)
Ari Zimran, Jeffrey Szer, Michal Becker-Cohen, Sjoerd Jens, Claudia Cozma, Shoshana Revel-Vilk
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy. Journal of clinical medicine 12 (6) (2023)
Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, Shoshana Revel-Vilk
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease. International journal of molecular sciences 24 (4) (2023)
Michal Becker-Cohen, Ari Zimran, David Arkadir, Shoshana Revel-Vilk, Uri Bakeman, Jeff Szer
Has Parkinson Disease Gone to the Dogs? Movement disorders : official journal of the Movement Disorder Society 38 (2) (2023)
Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, Shoshana Revel-Vilk
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease. International journal of molecular sciences 24 (4) (2023)
Filipa Curado, Sabine Rösner, Susanne Zielke, Gina Westphal, Ulrike Grittner, Volha Skrahina, Mohammed Alasel, Ahmad Mehmood Malik, Christian Beetz, Tobias Böttcher, Gal Barel, Ashish Prasad Sah, Tama Dinur, Nadeem Anjum, Quidad Ichraf, Yamna Kriouile, Zahra Hadipour, Fatemeh Hadipour, Shoshana Revel-Vilk, Claudia Cozma, Jörg Hartkamp, Huma Cheema, Ari Zimran, Peter Bauer, Arndt Rolfs, null null
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study. Diagnostics (Basel, Switzerland) 13 (17) (2023)
Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, Shoshana Revel-Vilk
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease. International journal of molecular sciences 24 (4) (2023)
Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, Ozlem Goker-Alpan, Heather Lau, Elena Lukina, Shoshana Revel-Vilk, Maurizio Scarpa, Jaco Botha, Noga Gadir, Ari Zimran, null null
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11 , 5158". Journal of clinical medicine 12 (12) (2023)
Shoshana Revel-Vilk, Ari Zimran, Majdolen Istaiti, Liat Azani, Varda Shalev, Gabriel Chodick, Orly Manor, Ora Paltiel
Cancer Risk in Patients with Gaucher Disease Using Real-World Data. Journal of clinical medicine 12 (24) (2023)
Majdolen Istaiti, Dafna Frydman, Tama Dinur, Jeffrey Szer, Shoshana Revel-Vilk, Ari Zimran
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. International journal of molecular sciences 24 (7) (2023)
Shoshana Revel-Vilk, Ari Zimran, Majdolen Istaiti, Liat Azani, Varda Shalev, Gabriel Chodick, Orly Manor, Ora Paltiel
Cancer Risk in Patients with Gaucher Disease Using Real-World Data. Journal of clinical medicine 12 (24) (2023)
Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, Shoshana Revel-Vilk
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease. International journal of molecular sciences 24 (4) (2023)
Michal Becker-Cohen, Ari Zimran, David Arkadir, Shoshana Revel-Vilk, Uri Bakeman, Jeff Szer
Has Parkinson Disease Gone to the Dogs? Movement disorders : official journal of the Movement Disorder Society 38 (2) (2023)
Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, Ozlem Goker-Alpan, Heather Lau, Elena Lukina, Shoshana Revel-Vilk, Maurizio Scarpa, Jaco Botha, Noga Gadir, Ari Zimran, null null
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11 , 5158". Journal of clinical medicine 12 (12) (2023)
Tama Dinur, Peter Bauer, Christian Beetz, Guido Kramp, Claudia Cozma, Marius-Ionuț Iurașcu, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Ari Zimran, Shoshana Revel-Vilk
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm? International journal of molecular sciences 23 (3) (2022)
Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, Ozlem Goker-Alpan, Heather Lau, Elena Lukina, Shoshana Revel-Vilk, Maurizio Scarpa, Jaco Botha, Noga Gadir, Ari Zimran, null null
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). Journal of clinical medicine 11 (17) (2022)
David Azoulay, Mira Naamad, Dafna Frydman, Ellen Broide, Ari Zimran, Galia Stemer, Shoshana Revel-Vilk
Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease. International journal of molecular sciences 23 (22) (2022)
Majdolen Istaiti, Michal Becker-Cohen, Tama Dinur, Shoshana Revel-Vilk, Ari Zimran
Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy. Journal of clinical medicine 11 (21) (2022)
Tama Dinur, Ulrike Grittner, Shoshana Revel-Vilk, Michal Becker-Cohen, Majdolen Istaiti, Claudia Cozma, Arndt Rolfs, Ari Zimran
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations. International journal of molecular sciences 22 (14) (2021)
Majdolen Istaiti, Shoshana Revel-Vilk, Michal Becker-Cohen, Tama Dinur, Uma Ramaswami, Daniela Castillo-Garcia, Magdalena Ceron-Rodriguez, Alicia Chan, Predrag Rodic, Radka Stefanova Tincheva, Walla Al-Hertani, Beom Hee Lee, Chia-Feng Yang, Beata Kiec-Wilk, Agata Fiumara, Barbara Rubio, Ari Zimran
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. American journal of hematology 96 (5) (2021)
Shoshana Revel-Vilk, Maria Fuller, Ari Zimran
Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. International journal of molecular sciences 21 (19) (2020)
Yishay Weill, Ari Zimran, David Zadok, Lauren M Wasser, Shoshana Revel-Vilk, Joel Hanhart, Tama Dinur, David Arkadir, Michal Becker-Cohen
Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease. International journal of molecular sciences 21 (19) (2020)
Ellen Sidransky, David Arkadir, Peter Bauer, Tama Dinur, Grisel Lopez, Arndt Rolfs, Ari Zimran
Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse? Movement disorders : official journal of the Movement Disorder Society 35 (2) (2019)
Noa Hurvitz, Tama Dinur, Michal Becker-Cohen, Claudia Cozma, Marina Hovakimyan, Sebastian Oppermann, Laura Demuth, Arndt Rolfs, Aya Abramov, Ari Zimran, Shoshana Revel-Vilk
Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease. International journal of molecular sciences 20 (12) (2019)
David Arkadir, Tama Dinur, Shoshana Revel-Vilk, Michal Becker Cohen, Claudia Cozma, Marina Hovakimyan, Sabrina Eichler, Arndt Rolfs, Ari Zimran
Glucosylsphingosine is a reliable response biomarker in Gaucher disease. American journal of hematology 93 (6) (2018)
Ari Zimran, Shoshana Revel-Vilk, Michal Becker-Cohen, Gaya Chicco, Naama Arbel, Arndt Rolfs, Jeffrey Szer
Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease. American journal of hematology 93 (9) (2018)
Elena A Lukina, Nora Watman, Marta Dragosky, Heather Lau, Elsa Avila Arreguin, Hanna Rosenbaum, Ari Zimran, Meredith C Foster, Sebastiaan J M Gaemers, M Judith Peterschmitt
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. American journal of hematology 94 (1) (2018)
Ari Zimran, Nadia Belmatoug, Bruno Bembi, Patrick Deegan, Deborah Elstein, Diego Fernandez-Sasso, Pilar Giraldo, Ozlem Goker-Alpan, Heather Lau, Elena Lukina, Zoya Panahloo, Ida Vanessa D Schwartz, null null
Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). American journal of hematology 93 (2) (2017)